RT Journal Article
T1 Resveratrol-Loaded Hydrogel Contact Lenses with Antioxidant and Antibiofilm Performance
A1 Vivero López, María
A1 Muras Mora, Andrea
A1 Silva, Diana
A1 Serro, Ana Paula
A1 Otero Casal, Ana María
A1 Concheiro Nine, Ángel Joaquín
A1 Álvarez Lorenzo, Carmen
K1 Antibiofilm
K1 Antioxidant
K1 Drug-eluting contact lenses
K1 Microbial keratitis
K1 Endophthalmitis
K1 Device-related ocular infections
AB Contact lenses (CLs) are prone to biofilm formation, which may cause severe ocular infections. Since the use of antibiotics is associated with resistance concerns, here, two alternative strategies were evaluated to endow CLs with antibiofilm features: copolymerization with the antifouling monomer 2-methacryloyloxyethyl phosphorylcholine (MPC) and loading of the antioxidant resveratrol with known antibacterial activity. MPC has, so far, been used to increase water retention on the CL surface (Proclear® 1 day CLs). Both poly(hydroxyethyl methacrylate) (HEMA) and silicone hydrogels were prepared with MPC covering a wide range of concentrations (from 0 to 101 mM). All hydrogels showed physical properties adequate for CLs and successfully passed the hen’s egg-chorioallantoic membrane (HET-CAM) test. Silicone hydrogels had stronger affinity for resveratrol, with higher loading and a slower release rate. Ex vivo cornea and sclera permeability tests revealed that resveratrol released from the hydrogels readily accumulated in both tissues but did not cross through. The antibiofilm tests against Pseudomonas aeruginosa and Staphylococcus aureus evidenced that, in general, resveratrol decreased biofilm formation, which correlated with its concentration-dependent antibacterial capability. Preferential adsorption of lysozyme, compared to albumin, might also contribute to the antimicrobial activity. In addition, importantly, the loading of resveratrol in the hydrogels preserved the antioxidant activity, even against photodegradation. Overall, the designed hydrogels can host therapeutically relevant amounts of resveratrol to be sustainedly released on the eye, providing antibiofilm and antioxidant performance
PB MDPI
YR 2021
FD 2021
LK http://hdl.handle.net/10347/25909
UL http://hdl.handle.net/10347/25909
LA eng
NO Pharmaceutics 2021, 13(4), 532; https://doi.org/10.3390/pharmaceutics13040532
NO This research was funded by MINECO (SAF2017-83118-R), Agencia Estatal de Investigación (AEI) Spain, Xunta de Galicia (ED431C 2020/17), FEDER, and Fundação para a Ciência e Tecnologia (FCT) Portugal (UIDB/00100/2020 and UIDB/04585/2020). M. Vivero-Lopez acknowledges Xunta de Galicia (Consellería de Cultura, Educación e Ordenación Universitaria) for a predoctoral research fellowship (ED481A-2019/120)
DS Minerva
RD 28 abr 2026